[1]傅 强,黄学阳,王建春,等.养阴散结汤辅助治疗分化型甲状腺癌疗效及对患者术后甲状腺、免疫功能和血清学指标的影响[J].陕西中医,2022,(8):1029-1031,1036.[doi:DOI:10.3969/j.issn.1000-7369.2022.08.009]
　FU Qiang,HUANG Xueyang,WANG Jianchun,et al.Effects of Yangyin Sanjie decoction on thyroid gland,immune function and serological indexes in postoperative patients with differentiated thyroid cancer[J].,2022,(8):1029-1031,1036.[doi:DOI:10.3969/j.issn.1000-7369.2022.08.009]
点击复制

养阴散结汤辅助治疗分化型甲状腺癌疗效及对患者术后甲状腺、免疫功能和血清学指标的影响
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2022年8期
页码:
1029-1031,1036
栏目:
临床研究
出版日期:
2022-08-05

文章信息/Info

Title:
Effects of Yangyin Sanjie decoction on thyroid gland,immune function and serological indexes in postoperative patients with differentiated thyroid cancer
作者:
傅 强; 黄学阳; 王建春; 黄亚兰; 蔡炳勤
(广东省中医院血管甲状腺外科,广东 广州 510220)
Author(s):
FU Qiang; HUANG Xueyang; WANG Jianchun; HUANG Yalan; CAI bingqin
(Department of Vascular and Thyroid Surgery,Guangdong Provincial Hospital of Traditional Chinese Medicine,Guangzhou 510220,China)
关键词:
分化型甲状腺癌;  养阴散结汤;  术后生存率;  甲状腺功能;  免疫功能
Keywords:
Differentiated thyroid carcinoma;  Yangyin Sanjie decoction;  Postoperative survival rate;  Thyroid function;  Immunity
分类号:
R 736.1
DOI:
DOI:10.3969/j.issn.1000-7369.2022.08.009
文献标志码:
A
摘要:
目的:探讨养阴散结汤对分化型甲状腺癌术后患者的临床疗效。方法:选择分化型甲状腺癌患者70例,按照治疗方式不同分为观察组和对照组各35例,其中对照组患者术后给予左旋甲状腺素片(L-T4)治疗,观察组在对照组的基础上加养阴散结汤治疗,观察两组患者治疗前后的甲状腺功能、免疫功能变化,比较治疗前后两组患者血清中细胞角蛋白19片段(Cyfra 21.1)、半乳糖血凝素-3(Gal-3)、血管内皮生长因子(VEGF)水平情况,比较两组疗效及不良反应情况。结果:治疗后,两组血清三碘甲状腺原氨酸(FT3)、血清游离甲状腺素(FT4)和血清促甲状腺素(TSH)水平明显改善,观察组更明显(P<0.05)。治疗后,对照组CD3+、CD4+、CD8+及CD4+/CD8+水平比较差异无统计学意义(P>0.05),观察组CD3+、CD4+、CD4+/CD8+水平均明显升高,CD8+水平下降(P<0.05)。治疗后,两组血清Cyfra 21.1、Gal-3水平升高,VEGF水平降低,观察组更明显(P<0.05)。观察组疗效优于对照组(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论:养阴散结汤在分化型甲状腺癌患者术后治疗中,疗效明显,可改善患者甲状腺功能及免疫功能,利于促进患者术后的恢复。
Abstract:
Objective:To explore the curative effect of Yangyin Sanjie decoction on postoperative patients with differentiated thyroid cancer.Methods:70 patients with differentiated thyroid cancer were selected retrospectively and divided into observation group(35 cases)and control group(35 cases)according to different treatment methods.The patients in the control group were treated with levothyroxine(L-T4)after operation.The observation group was treated with Yangyin Sanjie decoction on the basis of the control group.The changes of thyroid function and immune function before and after treatment were observed,the expression levels of cytokeratin 19 fragment(Cyfra 21.1),galactose hemagglutinin-3(Gal-3)and vascular endothelial growth factor(VEGF)in the serum of the two groups were compared before and after treatment.The curative effects of the two groups were observed.The adverse reactions of the two groups were observed.Results:After treatment,the levels of serum TSH,FT3 and FT4 in the two groups were significantly improved,especially in the observation group(P<0.05).After treatment,there was no significant change in the levels of CD3+,CD4+,CD8+ and CD4+/CD8+ in the control group(P>0.05).The levels of CD3+,CD4+,CD4+ / CD8+ in the observation group increased significantly and the level of CD8+ decreased(P<0.05).After treatment,the levels of serum Cyfra 21.1 and Gal-3 increased and VEGF decreased in the two groups,especially in the observation group(P<0.05).The total effective rate of the observation group was significantly higher than that of the control group(P<0.05).There was no difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Yangyin Sanjie decoction is effective in the postoperative treatment of patients with differentiated thyroid cancer.It can improve the thyroid function and immune function,and promote the recovery of prognosis.

参考文献/References:

[1] 陈肖玥,孙健雯,张国强,等.免疫检查点IDO-1、LAG-3、TIM-3与分化型甲状腺癌临床病理特征及预后的相关性[J].中华核医学与分子影像杂志,2021,41(4):196-200.
[2] 别克扎提?再孜提汉,潘金强,陈 辉,等.纳米碳对甲状腺癌患者甲状腺全切加双侧中央区清扫术中甲状旁腺功能的保护作用[J].医学综述,2019,25(22):184-188.
[3] 樊友本,田 文,房居高,等.局部晚期甲状腺癌手术治疗中国专家共识(2020版)[J].中国实用外科杂志,2020,40(4):14-21.
[4] 张业芳,成钊汀,秦春元.分化型甲状腺癌患者放射性131I治疗前低碘饮食的研究进展[J].中华护理杂志,2020,55(7):1107-1110.
[5] 高 明.甲状腺结节和分化型甲状腺癌诊治指南[J].中国肿瘤临床,2012,39(17):1249-1272.
[6] 李俊红,韦智晓,赵 蕾,等.分化型甲状腺癌患者术后首次行131I清除残余甲状腺组织的疗效及其影响因素[J].山东医药,2012,52(17):13-15.
[7] 卢承慧,李 娇,刘新峰,等.首次131I治疗后淋巴结显影伴治疗前刺激性Tg阴性的分化型甲状腺癌的治疗反应及影响因素分析[J].中华核医学与分子影像杂志,2020,40(1):21-26.
[8] Wu Y,Gao J,Wei J,et al.Development of flow cytometric assay for detecting papillary thyroid carcinoma related hsa-mir-146b-5p through toehold-mediated strand displacement reaction on magnetic beads[J].Molecules,2021,26(6):1628.
[9] 欧阳文奇,陈继东,向 楠,等.陈如泉辨证分型治疗乳头状甲状腺癌术后[J].中医药临床杂志,2020,32(1):24-26.
[10] 王树庚.健脾益气汤联合化疗治疗甲状腺癌及对患者免疫功能的影响[J].陕西中医,2016,37(10):1372-1373.
[11] 燕树勋,刘元炜,王 颖,等.分化型甲状腺癌术后中西医研究进展[J].世界中医药,2020,15(10):1505-1508.
[12] 石雅珺,院 倩,张广德.张广德教授辨治甲状腺癌术后诸症经验[J].世界中西医结合杂志,2021,16(8):1429-1432.
[13] 张莉萍,王松浩,朱 洁,等.养阴散结法辅助化疗治疗晚期胃癌阴虚证30例临床观察[J].湖南中医杂志,2021,37(9):8-12.
[14] 杨闪闪,文艳萍,娄彦妮,等.基于专利数据库分析中药复方治疗食管癌的用药规律[J].中国中西医结合消化杂志,2021,29(5):325-329.
[15] 高建强,王 娟,缪英霞,等.促甲状腺激素抑制疗法对老年甲状腺癌患者预后及血清CD44 V6表达水平的影响[J].川北医学院学报,2020,35(5):863-865,871.
[16] 周婷婷,张 艺,樊 展,等.补脾益肾方联合温针灸治疗重症肌无力疗效及对患者免疫功能的影响[J].陕西中医,2020,41(11):1665-1668.
[17] 吴 勇,陈 健,李成洁,等.不同浓度瑞芬太尼对胸腔镜下肺癌根治术患者围手术期免疫功能及肺功能的影响[J].中华肺部疾病杂志:电子版,2021,14(4):508-510.
[18] 田 亮,霍占江,王志杰,等.分化型甲状腺癌患者术后血清中Cyfra 21.1水平检测价值研究[J].中国耳鼻咽喉头颈外科,2020,27(10):564-567.
[19] 蒋玉欢,何本超,郑志刚,等.改良Miccoli微创术联合术后DC-CIK治疗甲状腺癌疗效及对患者血清Gal-3、sIL-2R水平的影响[J].陕西医学杂志,2020,49(11):1417-1421.
[20] 曲衍清,刘新强,崔莎莎,等.甲状腺癌组织中环氧合酶-2、CD163和血管内皮生长因子的表达及临床意义[J].中华生物医学工程杂志,2021,27(5):528-532.

备注/Memo

备注/Memo:
基金项目:国家中医药管理局科研项目(12BMGG02); 广东省中医院科研专项课题(E43610)
更新日期/Last Update: 2022-08-10